Enveric Biosciences, Inc. (ENVB)
Chart Events
Performance Outlook
| Previous Close | 2.3801 |
| Open | 2.5500 |
| Bid | 2.3000 x 1200 |
| Ask | 2.4600 x 800 |
| Day's Range | 2.2800 - 2.5500 |
| 52 Week Range | 1.3000 - 6.9800 |
| Volume | |
| Avg. Volume | 94,328 |
| Market Cap | 5.127M |
| Beta (5Y Monthly) | 0.36 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -11.5900 |
| Earnings Date | Nov 13, 2023 - Nov 17, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Apr 23, 2008 |
| 1y Target Est | 8.50 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for ENVB
Related Research
- Enveric Biosciences, Inc.Analyst Report: Oracle CorporationOracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.RatingFair ValueEconomic Moat16 hours agoMorningstar
Business WireEnveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates
CAMBRIDGE, Mass., September 20, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled "Carboxylated Psilocybin Derivatives and Methods of Using," pertaining to the Company’s EVM301 Series of molecules
Business WireEnveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023
CAMBRIDGE, Mass., September 18, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety and addiction disorders, today announced a poster presentation highlighting novel screening processes and technologies exclusive to Enveric’s EVM301 Series. The poster will be presented at the International Conference on Molecular Biology and Bioche
Business WireEnveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives
CAMBRIDGE, Mass., September 11, 2023--Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the filing of a provisional patent application to support its use of artificial intelligence (AI) based computational methods for identifying tryptamine derived new chemical entities (NCEs) and modeling inte
